Recursion Pharmaceuticals Raises $13M to Discover New Drugs Using Artificial Intelligence

SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals today announced its $12.9 million Series A round of funding, led by leading deep technology investor Lux Capital, with participation from Obvious VenturesEpic Ventures,Data CollectiveAME Cloud Ventures, Wild Basin Investments, and several prominent angel investors. Recursion has built a proprietary drug discovery platform that combines the best elements of high-throughput biology and automation with the newest advances in Artificial Intelligence (AI). The company has already identified novel uses for known drugs, bioactive compounds, and shelved pharma assets in the space of rare genetic disease. With its Series A funding, Recursion will develop its next-generation “Platform 2.0” – to scale its endeavor from the exploration of dozens of targets and diseases per year to thousands.